Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Neurology · Primary Dystonia

Modernizing Your Diagnosis: Beyond the DYT17 Label

At a Glance

A DYT17 diagnosis may come from an older chromosome-mapping label rather than a confirmed disease-causing gene. Modern specialist evaluation can include MRI, Wilson disease testing, a levodopa trial, and genetic testing; an uncertain genetic variant alone is not a diagnosis.

In the world of rare movement disorders, the way we identify conditions has changed dramatically. If you were originally diagnosed with DYT17, your diagnosis likely came from an era of “linkage mapping”—where scientists could see where a problem lived on a chromosome but couldn’t always find the exact gene [1][2]. Today, modern tools like Whole Exome Sequencing (WES) allow us to read your DNA letter-by-letter, making it possible to refine—or even change—a historical diagnosis.

The Diagnostic Foundation

A diagnosis of primary (isolated) dystonia is primarily clinical, meaning it is based on what a specialist sees during an exam [3]. To ensure your symptoms are truly an isolated condition, doctors use an individualized approach:

  • Brain MRI: An MRI is useful for assessing structural causes [4]. While a normal MRI helps rule out certain structural or metabolic issues, it does not definitively prove a genetic diagnosis or exclude all secondary causes [5][6].
  • Wilson’s Disease Testing: This is a treatable condition where copper builds up in the body. Because it can look exactly like dystonia, doctors may evaluate it using a combination of blood tests (ceruloplasmin), 24-hour urine copper collection, and a slit-lamp eye exam to look for copper rings in the cornea [7][8].
  • Levodopa Trial: A supervised, adequate trial of the medication levodopa may be used [9][4]. If your symptoms improve significantly, it suggests Dopa-Responsive Dystonia (DRD), but a lack of response does not exclude every treatable dystonia.

Moving Beyond Historical Labels

The DYT17 label is now considered a “historical locus.” While it was once mapped to a specific spot on chromosome 20, modern genetics has identified dozens of new, definitive genes that may better explain your symptoms [2][10].

If you haven’t had genetic testing in several years, a re-evaluation is often considered. Modern Next-Generation Sequencing (NGS) can look at hundreds of genes at once [11]. This is especially important for young-onset generalized dystonia, where the “diagnostic yield” (the chance of finding an answer) is as high as 51% in some specific study groups, though it is not an expectation for everyone [12][13]. A negative result does not invalidate your symptoms or treatment plan.

Understanding Your Results: The VUS

As you undergo modern testing, you may encounter a result called a Variant of Uncertain Significance (VUS).

  • What it is: A VUS means the lab found a variation in your DNA, but they don’t yet have enough evidence to know if it causes the disease or if it is just a harmless natural variation [14][15].
  • What to do: A VUS is not a confirmed diagnosis. It should not be used to make major medical decisions on its own [16]. Sometimes, a genetics professional will arrange testing of other family members to help interpret a VUS, but this requires specialized guidance [17].

Evaluations to Discuss with a Specialist

To ensure your diagnosis is as accurate and complete as possible, you and your doctor can consider the following individualized steps:

  1. Clinical History: Clear documentation of when symptoms started and how they spread [3].
  2. Brain MRI: To help evaluate for structural or “secondary” causes [4].
  3. Metabolic Screen: Specifically evaluating for mimics like Wilson’s disease when appropriate [18].
  4. Levodopa Trial: A supervised, documented attempt to see if the movements respond to dopamine [19].
  5. Modern Genetic Panel: A comprehensive test (like WES or a large dystonia panel) discussed with a genetic counselor [3][20].

Re-evaluating your diagnosis isn’t about losing your identity; it’s about using the best available science to ensure your treatment plan is built on the most accurate map possible.

Common questions in this guide

What does a DYT17 diagnosis mean today?
DYT17 is now considered a historical chromosome-region label rather than a definitive disease gene. Modern evaluation may identify a different genetic explanation for the dystonia or may not find a genetic cause.
Should I have updated genetic testing after an older DYT17 diagnosis?
A neurologist or genetics professional may recommend a broad dystonia panel or whole exome sequencing because these tests can examine many genes at once. Testing may refine the diagnosis, but a negative result does not invalidate symptoms or the existing treatment plan.
What tests help determine whether dystonia is primary or isolated?
The diagnosis is based mainly on a specialist’s clinical examination. Depending on the person, brain MRI, blood and urine testing for Wilson disease, a slit-lamp eye examination, and a supervised levodopa trial can help evaluate structural, metabolic, or treatable mimics.
Does a normal brain MRI confirm genetic dystonia?
No. A normal MRI can help rule out some structural problems, but it does not prove that dystonia is genetic or exclude every secondary cause.
What does a VUS mean on a dystonia genetic test?
A variant of uncertain significance, or VUS, is a DNA change that the laboratory cannot yet classify as disease-causing or harmless. It is not a confirmed diagnosis and should not guide major medical decisions by itself; a genetics professional may recommend family testing when appropriate.
Can a levodopa trial help identify a treatable form of dystonia?
A supervised, adequate levodopa trial may show whether symptoms improve in a pattern consistent with dopa-responsive dystonia. Lack of improvement does not rule out every treatable form of dystonia.

Get notified when new evidence is published on Primary dystonia, DYT17 type.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (20)
  1. 1

    Unmet Needs in Dystonia: Genetics and Molecular Biology-How Many Dystonias?

    Verbeek DS, Gasser T

    Frontiers in neurology 2016; (7()):241 doi:10.3389/fneur.2016.00241.

    PMID: 28138320
  2. 2

    Nomenclature of genetic movement disorders: Recommendations of the international Parkinson and movement disorder society task force.

    Marras C, Lang A, van de Warrenburg BP, et al.

    Movement disorders : official journal of the Movement Disorder Society 2016; (31(4)):436-57 doi:10.1002/mds.26527.

    PMID: 27079681
  3. 3

    Dystonia Diagnosis: Clinical Neurophysiology and Genetics.

    di Biase L, Di Santo A, Caminiti ML, et al.

    Journal of clinical medicine 2022; (11(14)) doi:10.3390/jcm11144184.

    PMID: 35887948
  4. 4

    Clinical Management of Dystonia in Childhood.

    Luc QN, Querubin J

    Paediatric drugs 2017; (19(5)):447-461 doi:10.1007/s40272-017-0243-3.

    PMID: 28620849
  5. 5

    Early-onset generalized dystonia caused by a new mutation in the KMT2B gene: Case report

    Rangel YA, Espinosa E

    Biomedica : revista del Instituto Nacional de Salud 2022; (42(3)):429-434 doi:10.7705/biomedica.6296.

    PMID: 36122281
  6. 6

    Consensus of Expert Opinion for the Diagnosis and Management of Hypermanganesaemia With Dystonia 1 and 2.

    Fang S, Clayton PT, Garg D, et al.

    Journal of inherited metabolic disease 2025; (48(3)):e70031 doi:10.1002/jimd.70031.

    PMID: 40320765
  7. 7

    Early Onset of Wilson Disease: Diagnostic Challenges.

    Wiernicka A, Dądalski M, Jańczyk W, et al.

    Journal of pediatric gastroenterology and nutrition 2017; (65(5)):555-560 doi:10.1097/MPG.0000000000001700.

    PMID: 28753182
  8. 8

    Usefulness of the Leipzig Score in the Diagnosis of Wilson's Disease - A Diagnostically Challenging Case Report.

    Basan NM, Sheikh Hassan M, Gökhan Z, et al.

    International medical case reports journal 2024; (17()):819-822 doi:10.2147/IMCRJ.S491888.

    PMID: 39364335
  9. 9

    Case Report: Guitarist's cramp as the initial manifestation of dopa-responsive dystonia with a novel heterozygous GCH1 mutation.

    Hasegawa T, Hosaka T, Harada R, et al.

    F1000Research 2021; (10()):361 doi:10.12688/f1000research.51433.1.

    PMID: 34394914
  10. 10

    Assessment of a Targeted Gene Panel for Identification of Genes Associated With Movement Disorders.

    Montaut S, Tranchant C, Drouot N, et al.

    JAMA neurology 2018; (75(10)):1234-1245 doi:10.1001/jamaneurol.2018.1478.

    PMID: 29913018
  11. 11

    A post hoc study on gene panel analysis for the diagnosis of dystonia.

    van Egmond ME, Lugtenberg CHA, Brouwer OF, et al.

    Movement disorders : official journal of the Movement Disorder Society 2017; (32(4)):569-575 doi:10.1002/mds.26937.

    PMID: 28186668
  12. 12

    Fifteen-minute consultation: Approach to investigation and management of childhood dystonia.

    Forman EB, King MD, Gorman KM

    Archives of disease in childhood. Education and practice edition 2021; (106(2)):71-77 doi:10.1136/archdischild-2019-318131.

    PMID: 32928841
  13. 13

    Scoring Algorithm-Based Genomic Testing in Dystonia: A Prospective Validation Study.

    Zech M, Jech R, Boesch S, et al.

    Movement disorders : official journal of the Movement Disorder Society 2021; (36(8)):1959-1964 doi:10.1002/mds.28614.

    PMID: 33949708
  14. 14

    Navigating variants of uncertain significance in genetic dyslipidemia: how to assess and counsel patients.

    Ison HE, Helm B, Kringlen G, Crawford P

    Current opinion in lipidology 2025; (36(2)):49-54 doi:10.1097/MOL.0000000000000971.

    PMID: 39950242
  15. 15

    Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.

    Richards S, Aziz N, Bale S, et al.

    Genetics in medicine : official journal of the American College of Medical Genetics 2015; (17(5)):405-24 doi:10.1038/gim.2015.30.

    PMID: 25741868
  16. 16

    Variant reclassification and clinical implications.

    Walsh N, Cooper A, Dockery A, O'Byrne JJ

    Journal of medical genetics 2024; (61(3)):207-211 doi:10.1136/jmg-2023-109488.

    PMID: 38296635
  17. 17

    A Homozygous c.74A>G Variant in PRKRA Causes DYT-PRKRA: Extensive Familial Segregation and a Variant of Uncertain Significance (VUS) Reclassification.

    Soleymani F, Piryaei F, Farhadi A, et al.

    Movement disorders : official journal of the Movement Disorder Society 2025; (40(10)):2257-2261 doi:10.1002/mds.30323.

    PMID: 40879515
  18. 18

    Role of serum ceruloplasmin in the diagnosis of Wilson's disease: A large Chinese study.

    Yang Y, Hao W, Wei T, et al.

    Frontiers in neurology 2022; (13()):1058642 doi:10.3389/fneur.2022.1058642.

    PMID: 36570465
  19. 19

    Relationship of Genotype, Phenotype, and Treatment in Dopa-Responsive Dystonia: MDSGene Review.

    Weissbach A, Pauly MG, Herzog R, et al.

    Movement disorders : official journal of the Movement Disorder Society 2022; (37(2)):237-252 doi:10.1002/mds.28874.

    PMID: 34908184
  20. 20

    Combined genomics and proteomics unveils elusive variants and vast aetiologic heterogeneity in dystonia.

    Zech M, Dzinovic I, Skorvanek M, et al.

    Brain : a journal of neurology 2025; (148(8)):2827-2846 doi:10.1093/brain/awaf059.

    PMID: 39937650

This page is for informational purposes only and does not constitute medical advice. Discuss genetic testing, MRI findings, Wilson disease screening, levodopa trials, and VUS results with your neurologist or genetic counselor.

Guide contents Primary dystonia, DYT17 type
Research & Literature
02 Recognizing the Patterns 04 Taking Control